Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

About Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KPTI
  • CUSIP: N/A
  • Web: www.karyopharm.com
Capitalization:
  • Market Cap: $501.55 million
  • Outstanding Shares: 47,139,000
Average Prices:
  • 50 Day Moving Avg: $11.02
  • 200 Day Moving Avg: $9.83
  • 52 Week Range: $6.27 - $14.63
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.61
  • P/E Growth: -0.14
Sales & Book Value:
  • Annual Revenue: $165,999.00
  • Price / Sales: 3,021.46
  • Book Value: $3.54 per share
  • Price / Book: 3.01
Profitability:
  • EBITDA: ($112,220,000.00)
  • Net Margins: -67,267.47%
  • Return on Equity: -70.42%
  • Return on Assets: -63.34%
Debt:
  • Current Ratio: 8.32%
  • Quick Ratio: 8.32%
Misc:
  • Average Volume: 182,409 shs.
  • Beta: 4.16
  • Short Ratio: 23.38
 

Frequently Asked Questions for Karyopharm Therapeutics (NASDAQ:KPTI)

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its earnings results on Tuesday, August, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. The company's quarterly revenue was down 95.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.84) earnings per share. View Karyopharm Therapeutics' Earnings History.

When will Karyopharm Therapeutics make its next earnings announcement?

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Karyopharm Therapeutics.

Where is Karyopharm Therapeutics' stock going? Where will Karyopharm Therapeutics' stock price be in 2017?

7 analysts have issued 1-year price targets for Karyopharm Therapeutics' stock. Their forecasts range from $14.00 to $19.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $16.00 in the next twelve months. View Analyst Ratings for Karyopharm Therapeutics.

What are analysts saying about Karyopharm Therapeutics stock?

Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:

  • 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (7/18/2017)
  • 2. Cantor Fitzgerald analysts commented, "Support for KPTI’s DLBCL program (SADAL) could build with a presentation at the EHA (Abstract S469) in June." (5/15/2017)
  • 3. HC Wainwright analysts commented, "Although selinexor is still technically on a partial clinical hold in the U.S., due to an omitted table in its most recent investigator's brochure, Karyopharm focused its 4Q call on the steady progress being made in its development across a range of indications. Having received its requested information, we believe the FDA should release the partial clinical hold well in advance of 4/9, and believe this hiccup will have no material impact on enrollment of the selinexor trials. On its call, Karyopharm noted that it had completed enrollment of its Phase 2/3 SEAL trial of selinexor in liposarcoma patients and expects to report topline data in mid-2017. While we do not currently include liposarcoma in our estimates, we note that selinexor had shown promising and durable stable disease outcomes in a Phase 1 study in sarcomas with a better PFS observed than the last prior regimen (19.4 v. 7.7 weeks) with 43% of liposarcoma patients achieving stable disease having a 4+ month response. Separately, Karyopharm provided updates on selinexor in multiple myeloma noting that the expanded STORM trial in penta-refractory myeloma patients was on track to read out in early-2018, the Phase 3 BOSTON trial was expected to start by April, and the Phase 1b/2 STOMP trial was to begin enrollment of a 44- patient Darzalex (daratumumab) combination arm, expected to read out in late-2017/early-2018. As of December, Karyopharm had a cash position of $175.5M, which the company believes sufficient to fund operations through 2018. In 2017, Karyopharm expects its cash burn to be $85-90M. We are maintaining our KPTI price target of $14, based on a sum-of-the-parts DCF consisting of $6 for selinexor in MM, $4 sel in DLBCL, and $4 cash." (3/17/2017)

Who are some of Karyopharm Therapeutics' key competitors?

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the folowing people:

  • Sharon Shacham Ph.D., President, Co-Founder, Chief Scientific Officer, Director
  • Michael G. Kauffman M.D. Ph.D., Co-Founder, Chief Executive Officer and Director
  • Michael Falvey, Chief Financial Officer, Executive Vice President, Treasurer, Principal Financial Officer, Principal Accounting Officer
  • Michael J. Todisco CPA, Vice President - Finance, Assistant Treasurer
  • Christopher B. Primiano, Vice President- Corporate Development, General Counsel, Secretary
  • Dilara McCauley Ph.D., Vice President - Product Leadership
  • Brian Austad Ph.D., Senior Director, Head - Pharmaceutical Sciences
  • Ran Frenkel, Chief Development Operations Officer
  • Barry E. Greene, Lead Independent Director
  • Mikael Dolsten M.D., Ph.D., Director

Who owns Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Nationwide Fund Advisors (0.22%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza and Ran Frenkel. View Institutional Ownership Trends for Karyopharm Therapeutics.

Who bought Karyopharm Therapeutics stock? Who is buying Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors. View Insider Buying and Selling for Karyopharm Therapeutics.

How do I buy Karyopharm Therapeutics stock?

Shares of Karyopharm Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of Karyopharm Therapeutics stock can currently be purchased for approximately $10.64.


MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (50.38% upside)
Consensus Price Target History for Karyopharm Therapeutics (NASDAQ:KPTI)
Price Target History for Karyopharm Therapeutics (NASDAQ:KPTI)
Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017Royal Bank Of CanadaReiterated RatingBuy$14.00N/AView Rating Details
10/13/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
10/12/2017Cantor FitzgeraldSet Price TargetBuy$18.00N/AView Rating Details
8/8/2017Canaccord GenuitySet Price TargetBuy$18.00HighView Rating Details
7/4/2017Robert W. BairdReiterated RatingOutperform$15.00HighView Rating Details
4/5/2017WedbushReiterated RatingOutperform$14.00MediumView Rating Details
3/17/2017HC WainwrightReiterated RatingBuy$14.00MediumView Rating Details
10/7/2016Leerink SwannReiterated RatingOutperform$18.00N/AView Rating Details
8/30/2016S&P Equity ResearchLower Price Target$9.06 -> $7.55N/AView Rating Details
5/27/2016Raymond James Financial, Inc.Initiated CoverageOutperform$13.00N/AView Rating Details
3/15/2016Bank of America CorporationDowngradeNeutral -> Underperform$26.00 -> $11.00N/AView Rating Details
3/14/2016J P Morgan Chase & CoLower Price TargetOverweight$20.00 -> $19.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$58.00 -> $28.00N/AView Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00N/AView Rating Details
(Data available from 10/24/2015 forward)

Earnings

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Earnings by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Earnings History by Quarter for Karyopharm Therapeutics (NASDAQ KPTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017        
8/8/2017Q2 2017($0.64)($0.64)$0.23 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.67)($0.71)$0.02 million$0.07 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.65)($0.65)$0.18 million$0.05 millionViewN/AView Earnings Details
11/7/2016Q316($0.81)($0.69)$0.18 million$0.05 millionViewListenView Earnings Details
8/4/2016Q216($0.76)($0.84)$0.18 million$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.74)($0.75)$0.30 millionViewN/AView Earnings Details
3/14/2016Q415($0.82)($0.81)$0.30 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.87)($0.85)$0.30 million$0.08 millionViewListenView Earnings Details
8/10/2015Q215($0.77)($0.92)$0.30 million$0.15 millionViewListenView Earnings Details
5/11/2015Q115($0.75)($0.74)$0.30 millionViewListenView Earnings Details
3/16/2015Q414($0.66)($0.79)$0.11 million$0.02 millionViewListenView Earnings Details
11/10/2014Q314($0.53)($0.61)$0.20 million$0.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.51)($0.55)$0.20 million$0.02 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.45)($0.46)$0.25 million$0.17 millionViewN/AView Earnings Details
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)
2017 EPS Consensus Estimate: ($2.52)
2018 EPS Consensus Estimate: ($2.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.66)($0.62)($0.63)
Q2 20173($0.64)($0.60)($0.62)
Q3 20173($0.64)($0.61)($0.63)
Q4 20173($0.65)($0.63)($0.64)
Q1 20181($0.64)($0.64)($0.64)
Q2 20181($0.59)($0.59)($0.59)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181($0.61)($0.61)($0.61)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Karyopharm Therapeutics (NASDAQ:KPTI)
Insider Ownership Percentage: 14.71%
Institutional Ownership Percentage: 58.97%
Insider Trades by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Insider Trades by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Christopher Brett PrimianoSVPSell1,500$12.00$18,000.00View SEC Filing  
10/2/2017Mansoor Raza MirzaDirectorSell2,000$12.00$24,000.00View SEC Filing  
9/15/2017Christopher Brett PrimianoSVPSell2,000$11.00$22,000.00View SEC Filing  
9/15/2017Mansoor Raza MirzaDirectorSell2,882$11.00$31,702.00View SEC Filing  
9/11/2017Mansoor Raza MirzaDirectorSell118$11.00$1,298.00View SEC Filing  
8/29/2017Christopher Brett PrimianoSVPSell2,195$10.00$21,950.00View SEC Filing  
6/26/2017Christopher Brett PrimianoSVPSell805$10.03$8,074.15View SEC Filing  
11/14/2016Ran FrenkelInsiderSell3,309$10.06$33,288.54View SEC Filing  
6/23/2016Ltd ChioneMajor ShareholderSell18,824$8.03$151,156.72View SEC Filing  
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.74View SEC Filing  
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.61View SEC Filing  
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.00View SEC Filing  
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.75View SEC Filing  
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.04View SEC Filing  
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.36View SEC Filing  
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.00View SEC Filing  
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.06View SEC Filing  
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.28View SEC Filing  
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.00View SEC Filing  
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.00View SEC Filing  
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.32View SEC Filing  
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.00View SEC Filing  
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Karyopharm Therapeutics (NASDAQ:KPTI)
Latest Headlines for Karyopharm Therapeutics (NASDAQ:KPTI)
Source:
Loading headlines, please wait.

Social

Chart

Karyopharm Therapeutics (KPTI) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.